DURECT (NASDAQ:DRRX) Raised to “Hold” at ValuEngine
DRRX has been the topic of a number of other research reports. BidaskClub cut shares of DURECT from a strong-buy rating to a buy rating in a research report on Friday, February 7th. Cantor Fitzgerald initiated coverage on shares of DURECT in a research report on Monday, November 18th. They issued a buy rating and a $5.00 target price on the stock. Craig Hallum began coverage on shares of DURECT in a research report on Wednesday, January 22nd. They issued a buy rating on the stock. B. Riley began coverage on shares of DURECT in a research report on Friday, January 31st. They issued a buy rating and a $5.00 price objective on the stock. Finally, HC Wainwright restated a buy rating and issued a $5.50 price objective on shares of DURECT in a research report on Friday, January 3rd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. DURECT currently has a consensus rating of Buy and a consensus target price of $4.40.
Shares of DURECT stock traded down $0.14 on Tuesday, hitting $1.96. 938,359 shares of the company traded hands, compared to its average volume of 2,172,034. The firm’s 50-day simple moving average is $2.40 and its 200 day simple moving average is $1.96. The company has a current ratio of 1.81, a quick ratio of 1.72 and a debt-to-equity ratio of 1.04. The company has a market cap of $340.48 million, a P/E ratio of -14.00 and a beta of 2.12. DURECT has a 12-month low of $0.50 and a 12-month high of $3.95.
Institutional investors and hedge funds have recently made changes to their positions in the company. Janney Montgomery Scott LLC bought a new stake in shares of DURECT during the 4th quarter valued at about $46,000. Commonwealth Equity Services LLC boosted its stake in DURECT by 36.9% during the third quarter. Commonwealth Equity Services LLC now owns 25,955 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 7,000 shares in the last quarter. Squarepoint Ops LLC bought a new stake in DURECT during the third quarter worth about $55,000. UBS Group AG boosted its stake in DURECT by 168.7% during the fourth quarter. UBS Group AG now owns 18,979 shares of the specialty pharmaceutical company’s stock worth $72,000 after acquiring an additional 11,916 shares in the last quarter. Finally, Alambic Investment Management L.P. bought a new stake in DURECT during the fourth quarter worth about $81,000. 30.51% of the stock is currently owned by hedge funds and other institutional investors.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand.
See Also: Google Finance Portfolio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.